1-[2-(2,2,2,-Trifluoroethoxy)phenyl]-4-[3-(N-phthalimido)propyl]piperazine | 334930-12-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪烷类
• 英文名称: 1-[2-(2,2,2,-Trifluoroethoxy)phenyl]-4-[3-(N-phthalimido)propyl]piperazine
• 英文别名: 2-[3-[4-[2-(2,2,2-Trifluoroethoxy)phenyl]piperazin-1-yl]propyl]isoindole-1,3-dione
• CAS: 334930-12-0
• 化学式: C₂₃H₂₄F₃N₃O₃
• 分子量: 447.457
• InChiKey: DHPIZGHXLLWIPK-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4
• 重原子数：
  32
• 可旋转键数：
  7
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.39
• 拓扑面积：
  53.1
• 氢给体数：
  0
• 氢受体数：
  8

反应信息

• 作为反应物：
  描述：

  1-[2-(2,2,2,-Trifluoroethoxy)phenyl]-4-[3-(N-phthalimido)propyl]piperazine 在 肼 作用下， 以78%的产率得到1-(3-Aminopropyl)-4-[2-(2,2,2-trifluoroethoxy)-phenyl]-piperazine
  参考文献：
  名称：

  Isoxazolecarboxamide derivatives

  摘要：

  该发明涉及新型N-(取代苯基)-N′-[ω-(3-取代苯基-4-异噁唑甲酰胺)烷基]哌嗪，它们的N-氧化物以及其药用可接受的盐。这些化合物具有增强的α1-肾上腺素受体选择性和降低血压活性较低。这些化合物在治疗下尿路梗阻综合征，包括良性前列腺增生（BPH），以及治疗下尿路症状（LUTS）和神经源性下尿路功能障碍（NLUTD）等疾病方面具有用途。

  公开号：

  US06365591B1
• 作为产物：
  描述：

  硝苯酚 在 palladium on activated charcoal 氢气 、 potassium carbonate 、 sodium iodide 作用下， 以 乙醇 、 二乙二醇二甲醚 、 N,N-二甲基甲酰胺 为溶剂， 90.0~140.0 ℃ 、101.33 kPa 条件下， 反应 38.5h， 生成 1-[2-(2,2,2,-Trifluoroethoxy)phenyl]-4-[3-(N-phthalimido)propyl]piperazine
  参考文献：
  名称：

  N-Arylpiperazinyl-N‘-propylamino Derivatives of Heteroaryl Amides as Functional Uroselective α₁-Adrenoceptor Antagonists

  摘要：

  Novel arylpiperazines were identified as alpha(1)-adrenoceptor(BR) subtype-selective antagonists by functional in vitro screening. 3-[4-(ortho-Substituted phenyl)piperazin-1-yl]propylamines were derivatized with N,N-dimethyl anthranilamides, nicotinamides,;as well as carboxamides of quinoline, I,8-naphthyridine, pyrazolo[3,4-b]pyridine, isoxazolo[3,4-b]pyridine, imidazo[4,5-b]pyridine, and pyrazolo[1,5-a]pyrimidines. Strips of rabbit bladder neck were employed as a predictive assay for antagonism in the human lower tract. Rings of rat aorta;a were used as a ''negative screen'' for the test antagonists. Binding to alpha(1)-ARs was relatively sensitive to size and electronic features of the arylpiperazine portion of the antagonists and permissive to these features on the heteroaryl carboxamide side. These structure-affinity findings were exploited to produce nicotinamides (e.g, 13ii and 25x) and pyrazolo[3,4-b]pyridines (e.g. 37f and 37y) ligands with nanomolar affinity at the alpha(1)-AR subtype prevalent in the human lower urinary tract (pA(2) values: 8.8, 10.7, 9.3, and 9.9, respectively) and displaying 2-3 orders of magnitude selectivity over the alpha(1D)-AR.

  DOI：

  10.1021/jm970166j

文献信息

• Adrenergic receptor antagonists selective for both alpha1A-and alpha1D-subtypes and uses therefor
  申请人：Recordati S.A., Chemical and Pharmaceutical Company

  公开号：US20020183290A1

  公开（公告）日：2002-12-05

  Described are derivatives with an adrenergic antagonistic activity and, in particular, high selectivity for &agr; 1a - and &agr; 1d -adrenergic receptors compared to &agr; 1b -receptors. This selectivity profile suggests the use of these derivatives in the treatment of symptoms of the lower urinary tract, including those associated to benign prostatic hyperplasia, without the side effects associated with hypotensive activity.

  描述了具有肾上腺素拮抗活性的衍生物，特别是相对于α1b-受体具有较高选择性的α1a-和α1d-肾上腺素受体。这种选择性配置表明这些衍生物可用于治疗下尿路症状，包括与良性前列腺增生相关的症状，而不会出现与降压活性相关的副作用。
• ISOXAZOLECARBOXAMIDE DERIVATIVES
  申请人：RECORDATI INDUSTRIA CHIMICA E FARMACEUTICA S.p.a.

  公开号：EP1226131B1

  公开（公告）日：2003-12-17
• US6365591B1
  申请人：——

  公开号：US6365591B1

  公开（公告）日：2002-04-02
• US6680319B2
  申请人：——

  公开号：US6680319B2

  公开（公告）日：2004-01-20